Company intelligence / Profile preview
Shenzhen Haoshi Biotechnology Co., Ltd.
Shenzhen, Guangdong Sheng* (*Province), Chinahaoshibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shenzhen Haoshi Biotechnology is a private Chinese biotech company focused on developing next-generation cellular immunotherapies, particularly chimeric antigen receptor T-cell (CAR-T) therapies targeting Claudin18.2 for advanced pancreatic cancer and CD19 for refractory mixed phenotype acute leukemia. Published results indicate high efficacy in preclinical models and individual patient cases, with ongoing research into safety strategies for these potent therapies.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyMass spectrometry-based diagnostics (inferred from related company activities, but not directly confirmed for this entity)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shenzhen Haoshi Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Haoshi Biotechnology Co., Ltd..